Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disease caused by relentless accumulation of ATTR amyloid in the heart [1]. The past 20 years has seen ATTR-CM evolve from a seemingly very rare and untreatable disorder into a relatively common one for which a remarkable range of novel therapies are now available with several more in advanced stages of development [2]. Just one patient was diagnosed with ATTR-CM during the first year after the UK National Amyloidosis Centre opened its doors in 1999, through an endomyocardial biopsy performed on suspicion of hypertrophic cardiomyopathy.
